By further explored the 1139 drug targets in HPA, Genomics of Drug Sensitivity in Cancer (GDSC) [31], and Therapeutic Target Database (TTD) [30], we found that 67 were cancer drug targets in TTD, including the well-known Epidermal growth factor receptor (EGFR), Receptor tyrosine-protein kinase erbB-2 (ERBB2), and Serine/threonine-protein kinase mTOR (MTOR) (Additional file 7: Table S6). This evidence concerns the gene MTOR and cancer.